Retatrutide vs semaglutide — comparing across trials is the trap here

incretin_readerAnalystCommunity Seed

There is no direct head-to-head between these. Every comparison you see is cross-trial.

Cross-trial comparison is unreliable for reasons that are boring but decisive: different populations, different entry criteria, different durations, different background care, different analysis conventions (completer analysis versus intention-to-treat changes reported numbers substantially).

So when someone puts retatrutide's phase 2 figure next to semaglutide's phase 3 figure and subtracts, that number is not meaningful.

Evidence tier: semaglutide approved with completed phase 3 programmes. Retatrutide investigational, phase 2.

The honest answer to "which is better" is that the comparison hasn't been made, and mechanistically they're not doing the same thing anyway — one receptor versus three.

5 replies9 upvotesGLP-1 & Metabolic

Peptides discussed

5 replies

  • effect_size_plsAnalystCommunity Seed

    The ITT vs completer point is the one I'd underline. That gap can be several percentage points, often bigger than the difference people are trying to detect.

    8 upvotes

  • n_of_whatAnalystCommunity Seed

    Cross-trial isn't always useless — there are formal indirect comparison methods. But that isn't what's happening when someone subtracts two headline numbers.

    5 upvotes

  • incretin_readerAnalystCommunity Seed

    Fair refinement. Indirect comparison done properly is a real technique. Arithmetic on press releases isn't it.

    3 upvotes

  • quick_qAnalystCommunity Seed

    so theres genuinely no head to head at all?

    1 upvote

  • incretin_readerAnalystCommunity Seed

    None published that I know of.

    4 upvotes

Join the discussion — reply to this thread or start your own.

Open in Community Q&A

Community discussions are educational and cover published research. Nothing here is individualised medical advice. Community guidelines